SOURCES AND EFFECTS OF REACTIVE OXYGEN INTERMEDIATES IN THE BRAIN

大脑中活性氧中间体的来源和作用

基本信息

项目摘要

Del Rio Hortega in 1919 was the first person to recognize the importance of microglia. They are the brain macrophages or phagocytes, which also release reactive oxygen species. Their function is to get rid of unwanted cellular debris and also to kill invading microorganisms. An oxygen burst is generated by the hexose monophosphatase shunt producing the superoxide anion by the NADPH oxidase at the membrane. Phorbol myristate acetate (PMA) acts directly on this mechanism. We investigated the effect of beta amyloid (A-beta) on the production of superoxide anion of activated microglia. A-beta (1-40) is derived from the amyloid precursor protein, which contains about 700 amino acids. The cysteine rich section contains a site which can reduce cupric ions to cuprous ions. A-beta has an extracellular domain as well as a membrane domain. We experimented on activated hamster microglia and human monocyte derived macrophages with PMA, and found that additional exposure to A-beta (1-40) produced only a small quantity of superoxide anion. However, when the microglia were primed or pretreated with A-beta followed by PMA activation, there was a larger increase in superoxide anion production. Without PMA, the superoxide production was reduced to the value obtained in the presence of A-beta (1-40), which was greater than the non-primed and non-stimulated case. The conclusion is that there is another site responsible for the superoxide production. Perhaps this site is the mitochondrion. In Alzheimer's disease, A-beta (1-40) is located in the plaque periphery, where it causes the resting microglia found in plaques to produce damaging reactive oxygen species, which can attack the most vulnerable part of the nervous system, the synapses. Microglia are not able to destroy the plaques because they are composed of beta pleated sheets, which are only soluble in formic acid.
1919年,Del bbbbo Hortega是第一个

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DANIEL L GILBERT其他文献

DANIEL L GILBERT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DANIEL L GILBERT', 18)}}的其他基金

SOURCES AND EFFECTS OF REACTIVE OXYGEN INTERMEDIATES IN THE BRAIN
大脑中活性氧中间体的来源和作用
  • 批准号:
    6290617
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Developing multitarget enzyme inhibitors as safe and effective anti-migraine treatments
开发多靶点酶抑制剂作为安全有效的抗偏头痛治疗方法
  • 批准号:
    10714658
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
  • 批准号:
    10395608
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
  • 批准号:
    10576908
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
The Development and Study of Novel Lipopeptide Antibiotics and Enzyme Inhibitors
新型脂肽抗生素和酶抑制剂的开发与研究
  • 批准号:
    RGPIN-2017-04233
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
  • 批准号:
    10166534
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Novel Enzyme Inhibitors in the Immune Evasion Repertoire of Staphylococcus aureus (Equipment Supplement)
金黄色葡萄球菌免疫逃逸的新型酶抑制剂(设备补充)
  • 批准号:
    10796329
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
  • 批准号:
    10259832
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
  • 批准号:
    10642850
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
The Development and Study of Novel Lipopeptide Antibiotics and Enzyme Inhibitors
新型脂肽抗生素和酶抑制剂的开发与研究
  • 批准号:
    RGPIN-2017-04233
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
    Discovery Grants Program - Individual
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
  • 批准号:
    10408178
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了